Pfizer wins full FDA approval for Braftovi in colorectal cancer
Source: SeekingAlpha
2026-02-24 13:26:25 ET
More on Pfizer, Ono Pharmaceutical
- Pfizer: A Risky 6.3% Yield For Income-Oriented Investors
- Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
- Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
- CDC vaccine panel to meet in March after delay
- Pfizer strikes $495M deal for obesity drug rights in China
Read the full article on Seeking Alpha
For further details see:
Pfizer wins full FDA approval for Braftovi in colorectal cancer
Ono Pharmaceutical Co Ltd ADR
NASDAQ: OPHLY
OPHLY Trading
0.99% G/L:
$4.898 Last:
3,289 Volume:
$4.91 Open:
